Medical/Pharmaceuticals
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
* Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million * Healthy financial position with cash reserves of RMB 1,026.7 million as of December 31, 2023 and net loss narrowed by 57% from the past year * CStone established strategic collaborations with multip...
2024-03-27 22:00
2287
Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...
2024-03-27 11:24
1202
Innovative strides in medical-grade TPUs: ICP DAS-BMP to introduce groundbreaking solutions at CMEF and Medtec Japan
HSINCHU, March 27, 2024 /PRNewswire/ -- ICP DAS-BMP (Biomedical Polymers), Asia's leading medical TPU (thermoplastic polyurethane) manufacturer and supplier, will exhibit at the International Component Manufacturing and Design Show (ICMD, part of CMEF) and Medtec Japan inApril 2024. The company w...
2024-03-27 09:20
1013
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology a...
2024-03-27 08:00
1191
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain
LONDON, March 27, 2024 /PRNewswire/ -- Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a world-first bladder cancer sentinel lymph node (SLN) procedure with SENSEI®, Telix's miniature robotic-assisted gamma pro...
2024-03-27 05:59
548
Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias
EPLive 2024 is a two-day conference that draws the world's top cardiac electrophysiology experts AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on co...
2024-03-26 23:58
522
ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis
LYON, France, March 26, 2024 /PRNewswire/ -- Reportlinker announces the release
of the report "A White Paper To Understand The Market Structure Of Pediatric
Pertussis Hexavalent and Combination Vaccines
2024-03-26 21:00
805
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
* MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events * Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of t...
2024-03-26 19:00
819
Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been dosed inAustralia in the clinical study (JSKN033-101) of JSKN033, a subcutaneous formulation with HER2 bispecific antibody-conjugated drug and PD-L1 monoclonal antibody,...
2024-03-26 09:57
1067
Scivita Medical Expands Collaboration with Boston Scientific
SUZHOU, China, March 26, 2024 /PRNewswire/ -- Recently, Scivita Medical
Technology Co., Ltd. ("Scivita Medical") and Boston
Scientific Corporation (NYSE: BSX), a leading global medical technology
company, joined hands again to sign an expanded strategic cooperation
arrangement.
2024-03-26 09:30
1133
BioDuro-Sundia's Partner, DigmBio Announced IND Clearance from Korea MFDS for its Selective PARP1 Inhibitor DM5167
SHANGHAI, March 26, 2024 /PRNewswire/ -- BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breast cancer has been approved by Korea Food and Drug Administration (MFDS) for Investigational New Drug ...
2024-03-26 08:30
1049
GenieMD Awarded Frost & Sullivan's 2024 Company of the Year Award for Pioneering Virtual Chronic Disease Management Solutions Through Its Unified Virtual Care Platform
GenieMD offers a comprehensive virtual care platform, integrating telehealth, remote patient monitoring, chronic care management, and AI-driven insights to impact the treatment and management of chronic diseases. SAN ANTONIO, March 25, 2024 /PRNewswire/ -- Frost & Sullivan recently researched th...
2024-03-25 22:31
1257
Sirtex Medical Appoints Matt Schmidt as New Chief Executive Officer and Board of Directors Member
WOBURN, Mass., March 25, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, announced today the appointment ofMatt Schmidt as chief executive officer and board of directors member, effectiveMarch 25. Since joining Sirtex in 2023, Schmidt...
2024-03-25 20:00
1226
ANNOUNCEMENT OF 2023 ANNUAL RESULTS OF TONG REN TANG TECHNOLOGIES
BEIJING, March 25, 2024 /PRNewswire/ -- Tong Ren Tang Technologies Co. Ltd. (" Tong Ren Tang Technologies" or the "Group", 1666.HK) is pleased to announce the audited consolidated results of the Group for the year ended31 December 2023. In 2023, the Group's revenue amounted to RMB6.77 billion, rep...
2024-03-25 12:47
1803
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today inManila, wi...
2024-03-25 10:00
692
Advancing Healthcare Innovation: Juniper Biologics Recognized as the Best Novel Therapy R&D and Commercialization Company 2024 by APAC Insider
SINGAPORE, March 25, 2024 /PRNewswire/ -- Juniper Biologics
2024-03-25 09:51
753
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures CANBERRA, Australia, March 25, 2024 /PRNewswire/ -- The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Pro...
2024-03-25 08:04
703
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
2024-03-22 19:00
3340
The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine
SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC) were published o...
2024-03-22 18:42
2435
Antengene Announces Full Year 2023 Financial Results, Highlights Clinical Progress Across First-in-Class, Best-in-Class Pipeline
* Promising clinical activities and efficacies during dose escalations for four lead global rights programs targeting CD24, Claudin 18.2, CD73, and PD-L1/4-1BB * Positive, differentiated cervical cancer data advancing mTORC1/2 inhibitor on registrational track for APAC markets * RMB1.188 bi...
2024-03-22 18:00
5791
Week's Top Stories
Most Reposted
Protiviti Transforms Cyber Risk Consulting with CYFIRMA's Advanced Intelligence-Led Cybersecurity
[Picked up by 324 media titles]
2024-04-15 09:00Sephora appoints Xia Ding as Managing Director of Sephora Greater China
[Picked up by 309 media titles]
2024-04-15 17:33
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
[Picked up by 295 media titles]
2024-04-12 15:14
With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 280 media titles]
2024-04-18 21:26
Animated Life in Yunnan
[Picked up by 277 media titles]
2024-04-18 14:00
Most Read
AI-DOL: Revolutionising the Future of Entertainment with AI-Powered Virtual Idols
2024-04-12 15:14
6413
XCMG Machinery Launches Premium G2 Crane Brand
2024-04-12 14:39
6344
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
2024-04-12 20:08
4532
Sephora appoints Xia Ding as Managing Director of Sephora Greater China
2024-04-15 17:33
3804